190 results about "Nucleoside Reverse Transcriptase Inhibitor" patented technology

This invention relates to a 50% drug loaded compressed tablet formulation for efavirenz. Efavirenz is a non-nucleoside reverse trancriptase inhibitor being studied clinically for use in the treatment of HIV infections and AIDS.

The present invention provides compounds for treating or preventing an HIV infection, or treating AIDS or ARC comprising administering a compound according to formula I where Ar, R¹-R⁵, R^7a, R^7b, R^7c, R⁸-R¹⁰, X¹, X² m, n, o and p are as defined herein.

Various carbonyl amides are employed in vitro and in vivo as non-nucleoside inhibitors of a reverse transcriptase, and particularly of HIV reverse transcriptase. Therefore, contemplated compounds may be employed in the treatment of HIV infected patients. Further contemplated aspects include pharmaceutical compositions comprising therapeutically effective amounts of contemplated compounds.

The present invention relates to a compounds according to formula I, methods for treating diseases mediated by human immunodeficieny virus by administration of a compound according to formula I and pharmaceutical compositions for treating diseases mediated by human immunodeficieny virus containing a compound according to formula I where R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and R⁸ are as defined herein.

The invention relates to application of dimethyl dehydrated silybin in preparing medicaments for treating virus hepatitis B, in particular to the application of 7 and 20-position methyl substituted dehydrated silybin or pharmaceutically acceptable salts thereof in preparing medicaments for removing HBsAG and HBsAg and medicaments for inhibiting HBV DNA replication. The dehydrated silybin has remarkably HBsAg and HBeAg inhibiting activity, wherein the strength for removing the HBsAg and the HBeAg at the concentration of 20 milligram/milliliter is 88.9 percent and 84.1 percent respectively, which are 5.5 times and 5.0 times that of a positive contrast medicament. More importantly, the dehydrated silybin shows the HBV DNA inhibition ratio of about 99.6 percent at the concentration of 20 milligram/milliliter, the activity exceeds lamivudine by 23 percent, which is 2.6 times that of interferon. Therefore, favonolignan or pharmaceutically acceptable salts thereof can be predictably used for preparing the non-nucleoside reverse transcriptase inhibitor medicaments for removing the HBsAg and HBeAg, inhibiting HBV DNA replication and treating hepatitis B virus infection diseases.

A method of treating viral infections, particularly Hepatitis B (HBV) and Human Immunodeficiency Virus (HIV) infections, by administering Elvucitabine and a second active agent to a patient suffering viral infection is provided herein. The second active agent is, for example, an immunomodulatory compound, an anti-viral agent, or a combination comprising one or more of the foregoing active agents. For example the anti-viral agent may be a tyrosine kinase inhibitor, a CCR5 inhibitor, a non-nucleoside reverse transcriptase inhibitor, a protease inhibitor, an integrase inhibitor. Further provided herein are combination dosage forms comprising Elvucitabine and a second active agent. The combination dosage may be administered once per day. The Elvucitabine may be administered less frequently than the second active agent. Packaged pharmaceutical compositions comprising Elvucitabine, a second active agent, and instructions for using the composition for treating a viral infection by administering Elvucitabine and the second active agent are also provided.

The present invention relates to novel compositions comprising an excision-inhibiting bisphosphonate and a nucleoside reverse transcriptase inhibitor. The present invention also relates to methods for preventing or treating retrovirus-related diseases using a composition comprising a bisphosphonate and a nucleoside reverse transcriptase inhibitor. In a specific embodiment, the invention provides methods for preventing or treating AIDS by administering a bisphosphonate-based compound in combination with 3′-azido-3′-deoxythymidine (AZT) to patients infected with AZT-resistant HIV to improve the effectiveness of AZT therapy.

The present invention provides for compounds useful for treating an HIV infection, or preventing an HIV infection, or treating AIDS or ARC. The compounds of the invention are of formula I wherein A is A1, A2, A3 or A4 and R¹, R², R³, R^4a, R^4b, R⁵, R⁶, Ar, X¹, X², X⁴, X⁴ and X⁵ are as herein defined. Also disclosed in the present invention are methods of treating an HIV infection with compounds defined herein and pharmaceutical compositions containing said compounds.

This application concerns certain 4-cyanophenylamino-substituted bicyclic heterocycles of formula I

where the dashed line represents a double bond that may be located either between A and C(V) or between C(V) and D, where A is S or C(Z); D is S or C(W); provided that one and only one of A and D is S; where T is NH, O, or S; and where other substituents are defined herein. These compounds are non-nucleoside reverse transcriptase inhibitors and have potential as anti-HIV treatment.

This invention relates to novel pyrazole derivatives of formula I wherein R1 to R4 are as defined in the summary and pharmaceutically acceptable salts and solvates thereof, methods to inhibit or modulate Human Immunodeficiency Virus (HIV) reverse transcriptase with compounds of formula I and pharmaceutical compositions containing of formula I admixed with at least one solvent, carrier or excipient. The compounds are useful for treating disorders in which HIV and genetically related viruses are implicated

Compounds of Formula I:

are HIV reverse transcriptase inhibitors, wherein R¹, R², R^E, L, M and Z are defined herein. The compounds of Formula I and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.